Posted by Michael Wonder on 09 Feb 2018
60 Degrees Pharmaceuticals receives priority review designation for malaria drug
7 February 2018 - 60 Degrees Pharmaceuticals received priority review designation from the US FDA for tafenoquine for prevention of malaria in adults.
In January 2018, 60P received US FDA fast track designation for the use of tafenoquine to prevent malaria in adults traveling to areas where the disease is prevalent.
